Expression of p21(waf1/Cip1), MDM2 and p53 in vivo: Analysis of cytological preparations

Cytopathology

Volumn 7, Issue 5, 1996, Pages 340-351

  Dowell, S P ^a   McGoogan, E ^b   Picksley, S M ^a   El Deiry, W S ^c   Vogelstein, B ^d   Hall, P A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

cytology; immunohistochemistry; MDM2; p21(waf1 Cip1); p53; reactive mesothelium

Indexed keywords

PROTEIN P21; PROTEIN P53; BIOLOGICAL MARKER; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; TUMOR PROTEIN;

ARTICLE; ASCITES; CANCER CELL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MESOTHELIUM CELL; PLEURA EFFUSION; PRIORITY JOURNAL; BIOSYNTHESIS; CYTODIAGNOSIS; CYTOLOGY; EXUDATE; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEUTROPHIL;

BIOLOGICAL MARKERS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTODIAGNOSIS; CYTOLOGICAL TECHNIQUES; ENZYME INHIBITORS; EXUDATES AND TRANSUDATES; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NEUTROPHILS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029658820     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2303.1996.tb00313.x     Document Type: Article

References (57)

1. Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994; 5: 133-45.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
3. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 1992; 89: 9210-4.
4. Midgley CA, Owens B, Briscoe CV, Thomas DB, Lane DP, Hall PA. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995; 108: 1843-8.
5. Merritt AJ, Potten CS, Kemp CJ et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614-17.
6. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
7. Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-52.
8. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
9. Lane DP. A death in the life of p53. Nature 1993; 362: 786-7.
10. Gaelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-3.
11. Kern SE, Kinzer KW, Bruskein A et al. Identification of p53 as a sequence specific DNA-binding protein. Science 1991; 252: 1708-11.
12. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 1990; 249: 1049-51.
13. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-9.
14. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Human genomic DNA sequences define a consensus binding site for p53. Nature Genet 1992; 1: 45-49.
15. Funk WD, Pak DJ, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA binding site for human p53 complexes. Mol Cell Biol 1992; 12: 2866-71.
16. Kastan MB, Zhan Q, El-Deiry WS et al. A mammalian cell cycle checkpoint pathway utilising p53 and GADD45 is defective in ataxia telangiectasia. Cell 1992; 71: 587-97.
17. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by regulation of thrombospondin-1. Science 1994; 265: 1582-4.
18. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
19. Van Meir EG, Polverini PJ, Chazin VR, Huang H-JS, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994; 8: 171-6.
20. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-25.
21. waf1/Cip1 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-10.
22. waf1/Cip1 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
23. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
24. Dulic V, Kaufmann WK, Wilson SJ et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-23.
25. Shivji MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen (PCNA) is required for DNA excision repair. Cell 1992; 69: 657-76.
26. Li Y, Jenkins CW, Nichols MA, Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 1994; 9: 2261-8.
27. WAF1 and proliferating cell nuclear antigen. Curr Biol 1995; 5: 275-82.
28. Barak Y, Juven T, Haffner R, Oren M. MDM2 expression is induced by wild-type-p53 activity. EMBO J 1993; 12: 461-8.
29. Wu XW, Bayle JH, Olson DC, Levine AJ. The p53 MDM2 autoregulatory feedback loop. Genes & Dev 1993; 7: 1126-32.
30. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 1993; 90: 11623-7.
31. Otto A, Deppert W. Upregulation of mdm2 expression in Meth a tumour cells tolerating wild-type p53. Oncogene 1993; 8: 2591-603.
32. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO J 1991; 10: 1565-9.
33. Cahilly Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987; 13: 235-44.
34. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16-18.
35. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
36. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.
37. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
38. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-9.
39. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
40. Pietenpol JA, Tokino T, Thiagalingham S, El-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994; 91: 1998-2002.
41. Iggo R, Gatter K, Bartek J, Lane DP, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
42. Wynford-Thomas D. p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1992; 166: 329-30.
43. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry . . . revisited. J Pathol 1994; 172: 1-4.
44. Hall PA, McKee PH, Du Menage H, Dover R, Lane DP. High levels of p53 protein in UV irradiated normal human skin. Oncogene 1993; 8: 203-7.
45. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. The clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994; 54: 2914-8.
46. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p. 53. J Immunol Methods 1992; 151: 237-44.
47. (WAF1/CIP1) expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-9.
48. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993; 75: 765-78.
49. English D, Anderson BR. Single step separation of red blood cells, granulocytes and mononuclear leucocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunological Methods 1974; 5: 249-54.
50. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, a laboratory manual, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 1989.
51. El-Deiry WS, Harper JW, O'Connor PM et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
52. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, GiVol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391-5.
53. waf1/Cip1 RNA in human cells. Mol Carcinogen 1994; 11: 59-64.
54. Jiang H, Lin J, Su Z-Z, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397-406.
55. Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-7.
56. Halevy O, Novitvch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018-21.
57. Dowell S, Derias N, Wilson POG, Lane DP, Hall PA. Expression of p53 in reactive mesothelium. Histopathology 1993; 22: 96-97.